FDA approves first generic of Roche's flu drug

• The generic can treat uncomplicated flu in patients who have had symptoms for no more than 48 hours, and can also prevent flu after contact with an infected person
• Baloxavir marboxil is taken as a single oral dose, with common side effects including diarrhea, bronchitis, nausea, sinusitis, and headache
• The drug carries warnings about increased treatment-emergent resistance in patients younger than five years of age

Summary

The U.S. Food and Drug Administration approved the first generic version of Roche's Xofluza (baloxavir marboxil) on June 17, marking a significant development ahead of the upcoming flu season. Norwich Pharmaceuticals received approval for this generic alternative to Roche's single-dose influenza treatment.

Key Details:

The generic drug is approved for patients aged five years and older to treat uncomplicated flu in those who have experienced symptoms for no more than 48 hours. It can also be used as a preventative measure following contact with an infected person. The treatment is suitable for both healthy patients and those at high risk of flu-related complications.

Product Background:

Roche's original Xofluza was first FDA-approved in 2018 and is marketed in the U.S. through the company's Genentech unit. The medication is administered as a single oral dose, distinguishing it from multi-day flu treatment regimens.

Safety Profile:

Common side effects include diarrhea, bronchitis, nausea, sinusitis, and headache. The FDA noted warnings about increased treatment-emergent resistance in patients under five years of age.

Market Implications:

The generic approval will likely erode Roche's market exclusivity for this flu treatment, potentially reducing medication costs for consumers and insurers while increasing competitive pressure on the Swiss pharmaceutical company. The timing ahead of flu season positions Norwich Pharmaceuticals to capture market share in the influenza treatment segment, which could impact Roche's revenue from this product line going forward.